Riskpilot← Back to searchSign inGet full accessEgetis Therapeutics AB (publ)
ABActiveOrg 5567066724Klara Norra Kyrkogata 26Research and experimental development on natural sciences and engineering · NACE 7210Est. 20060 employees
Revenue 2024
SEK 99M
EBITDA margin
-99.0%
-24% vs 2023
Equity ratio
67.2%
Financial strength
Net profit 2024
SEK -308M
+6% vs 2023
| Revenue | SEK 99M | — |
| EBITDA | SEK -98M | -24% |
| Net profit | SEK -308M | +6% |
| Total assets | SEK 774M | +8% |
| Equity | SEK 520M | -3% |
| Employees | 0 | — |
Legal name
Egetis Therapeutics AB (publ)
Org number
5567066724
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
3 juli 2006
Share capital
SEK 20 000 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av en av ledamöterna i förening med Westerholm, Mervin Nicklas Mickael Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall ha till föremål för sin verksamhet att bedriva forskning, utveckling, tillverkning och försäljning av läkemedel samt därmed förenlig verksamhet.
Address
Klara Norra Kyrkogata 26
Phone
+46812130330
Email
nicklas.westerholm@egetis.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 22 591 | 1 000 | 0 | 0 | 99 000 |
| Staff expenses | — | — | −0 | — | — |
| EBITDA | −61 208 | −63 000 | 0 | −79 000 | −98 000 |
| Depreciation & amort. | −43 | −0 | −0 | −0 | — |
| EBIT | −61 251 | −63 000 | 0 | −79 000 | −98 000 |
| Net financials | 1 268 | 4 000 | 0 | −5 000 | −25 000 |
| Profit before tax | −127 982 | −194 000 | 0 | −326 000 | −308 000 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −127 982 | −194 000 | 0 | −326 000 | −308 000 |
| Item | 2021 | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 573 843 | 558 000 | 0 | 717 000 | 774 000 |
| Equity | 518 246 | 497 000 | 0 | 537 000 | 520 000 |
| Long-term debt | 0 | 0 | 0 | 109 000 | 84 000 |
| Short-term debt | 55 187 | 57 000 | 0 | 71 000 | 160 000 |
| Total debt | 55 187 | 57 000 | 0 | 180 000 | 244 000 |
EBITDA margin
-99.0%
This company
15.8%
Market median
-727% vs market
20212024
Equity ratio
67.2%
This company
38.2%
Market median
+76% vs market
20212024
Return on equity
-59.2%
This company
18.4%
Market median
-422% vs market
20212024
Net profit margin
-311.1%
This company
8.1%
Market median
-3941% vs market
20212024
Asset turnover
0.13×
This company
1.12×
Market median
-88% vs market
20212024
Debt / equity
0.49×
This company
0.62×
Market median
+21% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JE Chief Auditor | Chief Auditor | 2024 |
MN Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (3) | ||
AK Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
KJ Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
KL Chief Auditor | Chief Auditor | 2020 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (7) | ||
| Chairman | 2024 | |
| Board of Directors | 2026 | |
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2026 | |
| Board of Directors | 2020 | |
| Board of Directors | 2025 | |
| Former (5) | ||
| Chairman | 2022 – 2024 | |
| Board of Directors | 2020 – 2024 | |
| Chairman | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Egetis Therapeutics AB (publ) (this company)
Egetis Therapeutics Us IncEGETIS THERAPEUTICS US INCBoard members of Egetis Therapeutics AB (publ) also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Karin Siwertz | Chief Executive Officer | 0 companies |
| Kurt Jörgen Lövgren | Chief Executive Officer | 0 companies |
| Karl Leonard Daun | Chief Auditor | 0 companies |
| Johan Erik Niclas Bergenmo | Chief Auditor | 0 companies |
| Mervin Nicklas Mickael Westerholm | Chief Executive Officer | 0 companies |
| Mats Peter Blom | Chairman | 0 companies |
| Birgitte Volck | Board of Directors | 0 companies |
| Per Thomas Lönngren | Chairman | 0 companies |
| Behshad Sheldon | Board of Directors | 0 companies |
| Gunilla Christina Osswald | Board of Directors | 0 companies |
| Peder Sven Walberg | Board of Directors | 0 companies |
| Donovan Y Wu | Board of Directors | 0 companies |
| Per Håkan Albin Åström | Chairman | 0 companies |
| Lena Elisabeth Svanberg | Board of Directors | 0 companies |
| Sten Folke Nilsson | Board of Directors | 0 companies |
| Marie Ekström Trägårdh | Board of Directors | 0 companies |
| Margarida Maria Ferreria De Almeida Duarte | Board of Directors | 0 companies |